Danielle Antelfi
Analyst, EBS
Replay available
Boston Scientific Corporation (BSX) Q2 2025 Earnings Call
Boston Scientific Corporation (NYSE: BSX) Q2 2025 earnings conference call, held 2025-07-23. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Michael Mahoney
President & Chief Executive Officer
Ken Stein
Executive Vice President & President, Rhythm Management
Rick Wise
Analyst, CIFL
Michael Pollak
Analyst, Wolfe Research
Matthew O'Brien
Analyst, Piper Sandler
David Roman
Analyst, Goldman Sachs
Travis Steed
Analyst, Bank of America
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Boston Scientific Corporation.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.039 we've talked about in the past with some low-cost scope competitors in 00:00:05.039 -- 00:00:10.286 Asia and Europe, which our team has really done a nice job of addressing. 00:00:10.286 -- 00:00:14.653 So we anticipate some of that headwind being mitigated as we look to 2026. 00:00:14.653 -- 00:00:19.861 So despite that, really strong performance in endo, as you know, high-margin 00:00:19.861 -- 00:00:25.089 business for us as well. Also pleased to see the enhancement and improvement 00:00:25.089 -- 00:00:27.189 in neuromodulation. 00:00:27.858 -- 00:00:33.464 The team there grew strong double digits in DBS, and the relieving acquisition 00:00:33.464 -- 00:00:38.570 has been integrated extremely well and really providing strong accretive growth 00:00:38.570 -- 00:00:43.596 to the company and a wider solution for pain physicians. 00:00:43.596 -- 00:00:49.102 And we continue, I would say, to have improved momentum in spinal cord stimulation. 00:00:49.102 -- 00:00:53.928 The team made a number of commercial changes over the past year or so, and that team 00:00:53.928 -- 00:00:55.830 is starting to come together and strengthening. 00:00:55.830 -- 00:01:00.885 So we anticipate you know, continued momentum with that neuromodulation business 00:01:00.885 -- 00:01:05.732 over the horizon. And our urology business is a fantastic franchise. 00:01:05.732 -- 00:01:08.377 It's grown a little bit under what 00:01:08.377 -- 00:01:12.643 we typically expect them to deliver. And we signal that at the end of the first quarter 00:01:12.643 -- 00:01:16.770 call, given some supply chain constraints that we're working through, that will get better 00:01:16.770 -- 00:01:21.036 in the second half of the year. And also some low-cost competition, 00:01:21....